SCHEMBL3530398

SCHEMBL3530398

Cc1cccc(NC(=O)Nc2ccc(-c3coc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 19/20 0.79
FLT3 P36888 17/20 0.79
FLT1 P17948 14/20 0.79
AURKA O14965 13/20 0.79
ABL1 P00519 13/20 0.79
LCK P06239 13/20 0.79
CSF1R P07333 13/20 0.79
FGFR1 P11362 13/20 0.79
NEK2 P51955 13/20 0.79
ROCK1 Q13464 13/20 0.79
NTRK2 Q16620 13/20 0.79
MAP4K4 O95819 12/20 0.79
MET P08581 12/20 0.79
MAP4K2 Q12851 12/20 0.79
AURKB Q96GD4 12/20 0.79
PTK2 Q05397 11/20 0.79
NTRK1 P04629 11/20 0.79
RPS6KA3 P51812 11/20 0.79
FYN P06241 10/20 0.79
PIM1 P11309 8/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3530153 0.95 KDR (0.74) KDRFLT3FLT1AURKAABL1
SCHEMBL3530222 0.93 KDR (0.69) KDRFLT3FLT1AURKAABL1
SCHEMBL3524754 0.87 KDR (1.00) KDRFLT3FLT1AURKAABL1
SCHEMBL3534272 0.84 KDR (0.73) KDRFLT3FLT1AURKAABL1
SCHEMBL3529831 0.84 KDR (0.73) KDRFLT3FLT1AURKAABL1
SCHEMBL3528671 0.83 KDR (0.58) KDRFLT3FLT1AURKAABL1
SCHEMBL3533908 0.82 KDR (0.73) KDRFLT3FLT1AURKAABL1
SCHEMBL3531034 0.80 KDR (1.00) KDRFLT3FLT1AURKAABL1
SCHEMBL3528843 0.79 KDR (0.89) KDRFLT3FLT1AURKAABL1
SCHEMBL3531374 0.78 KDR (0.68) KDRFLT3FLT1AURKAABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885FLT3 25/4885FLT1 613/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885FLT3 25/4885FLT1 613/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885FLT3 25/4885FLT1 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.